These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin. Wang H, Li T, Chen S, Gu Y, Ye S. Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802 [Abstract] [Full Text] [Related]
10. Interferon regulatory factor 5 in the pathogenesis of systemic lupus erythematosus. Cham CM, Ko K, Niewold TB. Clin Dev Immunol; 2012 Mar 09; 2012():780436. PubMed ID: 23251221 [Abstract] [Full Text] [Related]
11. IFN-α production by plasmacytoid dendritic cell associations with polymorphisms in gene loci related to autoimmune and inflammatory diseases. Berggren O, Alexsson A, Morris DL, Tandre K, Weber G, Vyse TJ, Syvänen AC, Rönnblom L, Eloranta ML. Hum Mol Genet; 2015 Jun 15; 24(12):3571-81. PubMed ID: 25779693 [Abstract] [Full Text] [Related]
13. IRF5-mediated signaling and implications for SLE. Lazzari E, Jefferies CA. Clin Immunol; 2014 Aug 15; 153(2):343-52. PubMed ID: 24928322 [Abstract] [Full Text] [Related]
15. Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Cherian TS, Kariuki SN, Franek BS, Buyon JP, Clancy RM, Niewold TB. Arthritis Rheum; 2012 Oct 15; 64(10):3383-7. PubMed ID: 22674082 [Abstract] [Full Text] [Related]
16. Role of interferons in SLE. Bengtsson AA, Rönnblom L. Best Pract Res Clin Rheumatol; 2017 Jun 15; 31(3):415-428. PubMed ID: 29224681 [Abstract] [Full Text] [Related]
17. Systematic identification of novel SLE related autoantibodies responsible for type I IFN production in human plasmacytoid dendritic cells. Kassim SH, Jordan J, Schreiter J, Adhikarakunnathu S, Baribaud F, San Mateo L. Cell Immunol; 2013 Jun 15; 284(1-2):119-28. PubMed ID: 23973875 [Abstract] [Full Text] [Related]
18. Cause and consequences of the activated type I interferon system in SLE. Eloranta ML, Rönnblom L. J Mol Med (Berl); 2016 Oct 15; 94(10):1103-1110. PubMed ID: 27094810 [Abstract] [Full Text] [Related]
19. Genetic Versus Non-genetic Drivers of SLE: Implications of IRF5 Dysregulation in Both Roads Leading to SLE. Barnes BJ. Curr Rheumatol Rep; 2019 Jan 15; 21(1):2. PubMed ID: 30645688 [Abstract] [Full Text] [Related]
20. Anti-interferon alpha treatment in SLE. Kirou KA, Gkrouzman E. Clin Immunol; 2013 Sep 15; 148(3):303-12. PubMed ID: 23566912 [Abstract] [Full Text] [Related] Page: [Next] [New Search]